Lyell Immunopharma, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    €52.55K -53.1% -€295.51M +46.2% -562,285.2% -3.8K pp -€139.51M +0.6% -265,459.0% -1.4K pp
    €112.00K -99.8% -€202.15M +4,835.5% -180,486.2% -1.8K pp -€138.72M +10.8% -123,852.3% -1.2K pp
    €72.96M +695.1% -€4.10M -98.3% -5.6% +27 pp -€125.16M +139.2% -171.6% +4.0 pp
    €9.18M +37.3% -€245.97M +43.8% -2,680.8% -1.2 pp -€52.33M -44.5% -570.4% +8.4 pp
    €6.68M +1,080.5% -€171.05M +63.7% -2,559.7% +160 pp -€94.25M -297.0% -1,410.4% -99 pp
    €566.04K -€104.47M -18,456.0% €47.83M 8,450.7%

    Notifications